Do you have $20,000 to invest this month?
A good place to start could be with ASX 200 shares that have strong market positions, long-term growth runways, and the potential to keep compounding over time.
Listed below are three that analysts think could be worth a closer look in June.
Image source: Getty Images
Cochlear Ltd (ASX: COH)
The first ASX 200 share to look at is Cochlear. It is one of Australia's great global healthcare businesses, developing hearing implant technology that can make a life-changing difference for people with severe hearing loss.
This is not a short-term consumer product story. Cochlear operates in a specialist medical market where clinical trust, research, product quality, and surgeon relationships matter enormously.
The long-term demand drivers also remain attractive. Populations are ageing, awareness of hearing loss is increasing, and many people who could benefit from implantable hearing solutions still do not have access to them.
Cochlear can also benefit from upgrades, services, and ongoing innovation across its product portfolio.
Trading conditions have been tough recently, but Canaccord Genuity remains positive. It recently put a buy rating and $120.00 price target on its shares.
NextDC Ltd (ASX: NXT)
Another ASX 200 share that could be worth buying with the $20,000 is NextDC. It owns and operates data centres, which are becoming increasingly important as businesses shift more of their operations into the cloud.
This means that NextDC is also exposed to one of the biggest themes in global technology: artificial intelligence (AI), which requires enormous computing power, secure infrastructure, reliable energy, and high-performance data centre capacity. That could support long-term demand for NextDC's services.
NextDC does require significant capital to keep expanding, and investors should expect periods of heavy investment. But if demand for digital infrastructure keeps growing, the company could have a long runway ahead.
Morgans is bullish on NextDC and recently put a buy rating and $18.00 price target on its shares.
Pro Medicus Ltd (ASX: PME)
A third ASX 200 share to consider is Pro Medicus. It provides medical imaging software through its Visage platform. This software is used by hospitals and radiology groups to view, manage, and interpret large imaging files.
As hospitals are producing more scans, clinicians need fast access to images, and health systems want software that can handle large volumes without slowing down workflows.
And with the Visage platform the best in its class, demand has been very strong and revenue and earnings have been growing at an explosive rate.
Bell Potter is a big fan of the company. It has a buy rating and $226.00 price target on its shares.
